ライフサイエンスコーパス: academia

1 epresents a flashpoint for discussion across academia.

2 s both in the pharmaceutical industry and in academia.

3 campaigns in the pharmaceutical industry and academia.

4 and strengthening the societal leadership of academia.

5 emand the study of the role of mentorship in academia.

6 talented residents interested in careers in academia.

7 and institutional review board approval for academia.

8 requires participation of both industry and academia.

9 Organizational changes are also under way in academia.

10 bers of the FDA, other federal agencies, and academia.

11 dustry and, in some cases, to then return to academia.

12 taken up by more groups in both industry and academia.

13 nology and spin-off companies originating in academia.

14 earch, teaching, and service in industry and academia.

15 ise them about careers inside and outside of academia.

16 how science is conducted in industry versus academia.

17 revent more effective application of FBDD in academia.

18 most PDMS and plastic molding techniques in academia.

19 e attention of researchers from industry and academia.

20 but is sometimes used less systematically in academia.

21 pefully be useful for those pursuing FBDD in academia.

22 icologists, across government, industry, and academia.

23 toral researchers were focused on careers in academia.

24 debates about women's underrepresentation in academia.

25 y used as an oxidizing agent in industry and academia.

26 ct uniquely predictive of gender gaps across academia.

27 butes to the underrepresentation of women in academia.

28 tions between the biotechnology industry and academia.

29 ue in a pipeline traditionally geared toward academia.

30 ile empowering discovery across industry and academia.

31 r many research and clinical applications in academia.

32 with the majority (>60%) being supported by academia.

33 Women were more concentrated in academia (22% vs 14%, P = .009) and breast imaging (27%

34 Economic partnerships between industry and academia accelerate medical innovation and enhance patie

35 ender disparities appear to be decreasing in academia according to a number of metrics, such as grant

36 nal organisations, national governments, and academia all have responsibilities in ensuring that data

37 rtunities, and movement between industry and academia-almost unheard of two decades ago-now occurs re

38 ed they would spend most of their careers in academia and 15% thought research would be their major f

39 many are now considering careers outside of academia and are aware of numerous exciting career oppor

40 flexible and better connected to research in academia and biotechnology firms.

41 In 1992, in a collaboration between academia and biotechnology, my colleagues and I showed t

42 on of the Open AUC MWL detector developed in academia and first introduced in 2006 by Bhattacharya et

43 -based research centers and researchers from academia and government will undoubtedly continue to inc

44 lending is a common practice in industry and academia and has a large economic advantage.

45 Contributions from large companies, academia and high-tech start-ups are used to elucidate w

46 industries work alongside the scientists in academia and in government to set priorities, make decis

47 ibly changed for the modern chemist, both in academia and in industry.

48 n a major goal for many laboratories both in academia and in industry.

49 spectrometry (MS) is becoming widely used in academia and in pharmaceutical and biotechnology industr

50 ) is the focus of intensive research both in academia and in pharmaceutical companies.

51 nhibitors has been intensely pursued both in academia and in pharmaceutical companies.

52 bute to strengthening biomedical research in academia and in the biotechnology and pharmaceutical ind

53 Certainly research efforts, in academia and industry alike, are ongoing with the main a

54 potentials, it poses several challenges for academia and industry analysts alike.

55 cid and aryl halides are widely used in both academia and industry and are strategically important in

56 Scientists in both academia and industry are now using biosensors in areas

57 alyze multidisciplinary partnerships between academia and industry as scientists attempt to merge the

58 eives a lot of attention from researchers in academia and industry as this technology provides reduce

59 Speakers from academia and industry came together to provide up-to-dat

60 lysis, and manuscript preparation where both academia and industry can supply important insights.

61 to preempt growing concerns arising in both academia and industry for data-driven applications of bi

62 Finally, harmonization between academia and industry for more clinically relevant precl

63 th of "Big Pharma," the relationship between academia and industry has changed.

64 Functional genomics research within both academia and industry has led to the identification of m

65 In recent years, both academia and industry have foreseen the storage of natur

66 ts and the practitioners of this art both in academia and industry hopefully will continue to design

67 growing acceptance of relationships between academia and industry in the life sciences, systematic,

68 ssess the evolution of relationships between academia and industry over the past decade.

69 Increasingly, academia and industry seek to collaborate, and share res

70 ombines interdisciplinary knowledge from the academia and industry to facilitate technological conver

71 r sustainable chemicals and fuels has pushed academia and industry to search for alternative feedstoc

72 These models are already being utilized by academia and industry to search for genetic and chemical

73 nt years reporter genes have been applied in academia and industry to the study of ligand efficacy an

74 ence which included over 250 members of both academia and industry was a great opportunity to learn a

75 mentary solutions that leverage expertise of academia and industry were proposed to address them.

76 Key research thrusts in both academia and industry will speed this transition, and le

77 erent type of relationship is needed between academia and industry, and also within industry, to prom

78 MRI-based technologies, closer ties between academia and industry, and an expanded endeavour to shar

79 via extensive collaborative research between academia and industry, applying ingenious solutions and

80 ogy required for the work is similar between academia and industry, but the way in which these skills

81 Owing to their wide application in academia and industry, new methods and strategies for th

82 esearch and development is underway, both in academia and industry, to meet the demand for electric v

83 earch activity across the globe, and between academia and industry, to translate scientific discoveri

84 gistered for the conference, drawn both from academia and industry, with a wide range in experience a

85 -effects that draw great attention from both academia and industry.

86 government, non-governmental organisations, academia and industry.

87 fic aspects of genetic ancestry inference in academia and industry.

88 and SPECT/CT systems have been developed in academia and industry.

89 differences between research environments in academia and industry.

90 e and more popular for elemental analysis in academia and industry.

91 I owe much of my success to my mentors from academia and industry.

92 in the investigation of natural products in academia and industry.

93 eneral proving ground for excellence both in academia and industry.

94 duction of large-area graphene films in both academia and industry.

95 utics requires scientific activities in both academia and industry.

96 f disciplines has overcome obstacles in both academia and industry.

97 en a focus of many drug discovery efforts in academia and industry.

98 ealth, and thus attracts attention from both academia and industry.

99 In bridging the gap between academia and large pharmaceutical companies, the biotech

100 Studies from both academia and pharmaceutical companies have identified co

101 Despite considerable interest from both academia and pharmaceutical companies in the discovery a

102 at women face in moving through the ranks of academia and propose ways to increase women's representa

103 convened by the Council on Linkages Between Academia and Public Health Practice in 1995 to develop p

104 nd Clinical Immunology (EAACI), experts from academia and regulatory agencies met with chamber operat

105 ties, public health initiatives, healthcare, academia and scientific research, and data monitoring an

106 er it is possible to combine motherhood with academia and still be successful and happy.

107 k in partnership with both the scientists in academia and the government to identify a means of addre

108 icts of interest have driven a wedge between academia and the pharmaceutical and devices industries.

109 Research in both academia and the pharmaceutical industry has led to the

110 y the different medicinal chemistry teams in academia and the pharmaceutical industry to improve pote

111 has generated considerable interest in both academia and the pharmaceutical industry.

112 ality adjusted life years, were supported by academia, and evaluated non-pharmaceutical interventions

113 is that different incentives drive industry, academia, and funding bodies.

114 More than 300 participants from industry, academia, and government attended the symposium, which f

115 other stakeholders, such as the government, academia, and health care providers.

116 ed engagement of scientists from government, academia, and industry enabled multiple unanticipated an

117 nd resources from philanthropic foundations, academia, and industry to advance therapeutic discovery

118 artnerships across governments, health care, academia, and industry, and with the public, are essenti

119 nts, and work with leaders from governments, academia, and organizations to address and reduce avoida

120 h research funding and regulatory agencies), academia, and patient groups to discuss these challenges

121 borative approach from physicians, industry, academia, and regulatory bodies supporting great innovat

122 xicity and safety assessment, from industry, academia, and regulatory bodies, to specifically explore

123 Strong cooperation between industry, academia, and research institutions will be required to

124 abase (FAOSTAT)], the Australian government, academia, and the food industry.With the use of the FAOS

125 fecting rural areas as well as large cities, academia, and the military.

126 and local governments; professional bodies; academia; and the pharmaceutical industry met to review

127 rug sales, partnerships between industry and academia are essential to achieve the full promise of he

128 Industry and academia are finally coming to terms with the fact that

129 zed, researchers in industry, government and academia are increasingly examining liquid crystalline m

130 eat promise for improving gender equality in academia around the globe.

131 Its relevance applies to both industry and academia as an inherently direct and sustainable strateg

132 crofluidics has attracted much interest from academia as well as industry, since it potentially offer

133 dations for improving political diversity in academia bear the danger of imposing political interests

134 at included representatives from government, academia, business, and civil society and included exper

135 red for fundamental spectroscopic studies in academia but not in industrial processes.

136 he degree of intellectual freedom allowed in academia but offers an increased opportunity to see the

137 s how organizational changes in industry and academia can complement each other.

138 1), which brought together participants from academia, clinical practice, industry, and regulatory an

139 While scientists in academia continue to explore the multifactorial nature o

140 d discovery (FBLD) in industry as well as in academia creates a high demand for sensitive and reliabl

141 a public-private partnership among the FDA, academia, data owners, and the pharmaceutical industry t

142 a better feel for the challenges mothers in academia face, and the strategies that can be used to su

143 Multiple stakeholders, including academia, federal funding agencies, industry, scientific

144 r, the process by which devices arising from academia find their way to translation remains poorly un

145 cal development and funding of the study and academia for patient recruitment and participation in th

146 ntial to solve these issues which have beset academia for several decades.

147 , constitute a wake-up call for governments, academia, funders, and WHO to strengthen programmes and

148 ts, Local Authorities, Department of Health, academia, General Practice and Hospital Trusts and the t

149 dpoints, which requires collaboration across academia, government and industry.

150 It remains to be seen whether academia, government laboratories and contract houses wi

151 ists, toxicologists, and risk assessors from academia, government, and industry convened to discuss u

152 Methods This group convened experts from academia, government, and industry to review barriers to

153 equire concerted international efforts among academia, government, and industry.

154 ed Solutions to Obesity: What is the Role of Academia, Government, Industry, and Health care?" as a p

155 ) convened a think tank of stakeholders from academia, government, industry, and patient advocacy to

156 No one sector, academia, government, industry, or health care, has been

157 Wide consensus between academia, governmental regulators, and industry for furt

158 This porosity between industry and academia has created opportunities for more rapid transl

159 worst, the spawning of a company from within academia has the potential to use public employees, spac

160 ution Act," scientists in the government and academia have been able, in earnest, to consider what ty

161 Many life sciences trainees in academia have limited exposure to how the biotechnology/

162 epresenting government and private agencies, academia, health educators, and tobacco control experts)

163 gether communities who need these drugs with academia, health-care professionals, and pharmaceutical

164 In academia, however, fewer women reach top leadership posi

165 e documented underrepresentation of women in academia in general and cell biology in particular.

166 has attracted much attention in industry and academia in recent years.

167 ndations and standards for both industry and academia in the field of antituberculosis drug developme

168 ata submission from worldwide researchers at academia, industry and government agencies.

169 emergent challenges and offer suggestions to academia, industry and government on how best to expand

170 tools and data amongst scientists working in academia, industry and government.

171 isted of experts in xenotransplantation from academia, industry, and federal agencies, and the discus

172 of individuals with relevant expertise from academia, industry, and government to provide the nephro

173 stimulate and catalyze partnerships between academia, industry, and other sources of capital.

174 uding representatives from patients' groups, academia, industry, and regulatory agencies-is aimed at

175 litated a meeting represented by clinicians, academia, industry, and regulatory agencies.

176 nt (March 2008) public meeting, experts from academia, industry, and regulatory bodies discussed seve

177 national multidisciplinary group from within academia, industry, and the National Institutes of Healt

178 vascular drug development, stakeholders from academia, industry, regulatory bodies, and government ag

179 these meetings, a wide range of experts from academia, industry, the nonprofit sector, and the U.S. g

180 d for a consensus statement of standards for academia-industry interactions from the scientists' pers

181 The NEWMEDS consortium, an academia-industry partnership, assembled a database of o

182 The rise in academia-industry relationships has been accompanied by

183 ally receive little education about industry-academia interactions.

184 ent in the hierarchical ladder of Australian academia is a considerable waste of government investmen

185 We show that success in academia is predictable.

186 lable upon request for non-commercial use in academia (local hit table binary and indices are at ftp:

187 derstanding how institutional changes within academia may affect the overall potential of science req

188 CSF Tetrad graduates with diverse careers in academia, medicine, industry, and publishing, we hope th

189 e National Cancer Institute (NCI), NASA, and academia met in Bethesda to discuss major lung cancer is

190 These findings suggest that academia needs to carefully evaluate why these new polic

191 The relationship between industry and academia needs to evolve to maximize the opportunity.

192 with green chemistry leaders from industry, academia, nongovernmental institutions (NGOs), and gover

193 While industry and academia often partner for the performance of phase I st

194 er popular scoring functions in industry and academia on both prediction of binding affinity and "nat

195 idated or generally accepted definition from academia or regulatory authorities for this relevant pol

196 of closer interactions between industry and academia, other issues, such as conflicts of interest (b

197 vital for culture collections, industry and academia; particularly when addressing issues of intelle

198 ications of HAART, with representatives from academia, patient community, US Food and Drug Administra

199 government, medical professional societies, academia, patient groups, and industry gathered to brain

200 ts representing the pharmaceutical industry, academia, product development partnerships, and regulato

201 ng pathogens has become standard practice in academia, public health agencies, and large industries.

202 small-molecule screening in industry versus academia, recent developments in high-throughput screeni

203 t is possible to restore balance to industry-academia relationships, thereby promoting progress while

204 ation, more emphasis on commercialization by academia research field, and increased information on ho

205 government, industry, regulatory bodies, and academia should realign to ensure medical science is use

206 applied research, the roles of industry and academia, the concerns about xenotransplantation, and th

207 On April 17, 2010, scientists from academia, the National Cancer Institute (NCI), and the F

208 artnership comprised of representatives from academia, the pharmaceutical industry, and the federal g

209 Many simultaneous activities involving academia; the pharmaceutical, device, and biotechnology

210 d this new initiative to enable industry and academia to change the vector control paradigm for malar

211 g discovery researchers in both industry and academia to identify all the possible indications for ea

212 ment of both the pharmaceutical industry and academia towards the discovery of new chemotherapeutic a

213 first-rate example of collaboration between academia (University of California) and industry (Sangam

214 mpleted training (n = 192) were currently in academia versus 26% of nonparticipants (n = 676; P = .00

215 nvolving collaborations between industry and academia, we propose voluntary standards related to: 1)

216 ys an important role in both industry and in academia where selectivity, activity and stability are c

217 This development became very popular in academia, where instruments are not operated for you by

218 Increasing collaboration with academia will also become more important for accessing t

219 ooperation between industry, government, and academia will be key in establishing long-term strategie

220 to leverage the basic research expertise in academia with the pharmaceutical industry's knowledge in

221 peutics for neurodegenerative disease within academia, with a special focus on organizational issues.

222 iduals experience as they pursue a career in academia within seven STEM disciplines.

223 for predoctoral and postdoctoral trainees in academia, yet little attention is paid to preparation fo